NAFDAC Approves Vaccine For Cervical Cancer
The National Agency for Food and Drug Administration and Control (NAFDAC) has approved the use of HPV vaccine as single dose in the routine immunization against cervical cancer, beginning from the last quarter of 2023 with the national launch on 24th October. During a joint meeting alongside the National Primary Health Care Development Agency, the agencies agreed that the deployment of HPV vaccine can provide solid protection against cervical cancer caused by the human papillomavirus. The HPV vaccine which is giving in two or three doses is recommended for girls and boys within 11 and 12 years but can be administered as early as 9 years or as late as 26 years.